×
0 0 0 0 0 0 0 0
Stockreport

Akcea Reports Financial Results and Highlights for Second Quarter 2018

AKCEA THERAPEUTICS (AKCA)  More Company Research Source: GlobeNewswire
Last akcea therapeutics earnings: 8/6 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.akceatx.com/media-investors/press-releases
PDF TEGSEDI™ (inotersen) Approved in European Union             $382 million to fund the company through key milestones in 2019       Conference Call Webcast Monday, August 6, 4:30 p.m. ET at www.akceatx.com CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2018. The company reported a net loss for the three and six months ended June 30, 2018 on a GAAP basis of $62 million and $92 million, respectively, and on a pro forma basis of $50 million and $73 million, respectively. Akcea had $382 million of cash, cash equivalents and short-term investments as of June 30, 2018. “This is an incredibly exciting time for Akcea with TEGSEDI now approved in Europe and upcoming PDUFA dates in the US for WAYLIVRA™ (volanesorsen) and TEGSEDI.  We ar [Read more]

IMPACT SNAPSHOT EVENT TIME: AKCA
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS